Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Cancer
David Hong
Pancreas

Study Description

Eligibility

  • At time of enrollment, the patient must have received 4-6 months of active chemotherapy with FOLFIRINOX 98-12 cycles) or NALIRIFOX (8-12 cycles) or gemcitabine/na-paclitaxel (4-6 cycles) (1 regimen, no sequential chemotherapy)
  • Pathologically (histologically or cytologically) proven diagnosis of pancreatic ductal aadenocarcinoma
  • Age 18 and over
  • Not pregnant and Not nursing
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.